About: Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Creator	Lopes, Renato Gibson, C Granger, Christopher Alexander, John Arruda, Saba Campos De Albuquerque, Denilson D'andréa, Guilherme Feldman, Andre Ferreira De Souza, Olga Junqueira, Renata Macedo, Scarlatelli Mazza, Lilian Melo De Barros E Silva, Pedro Salvador, Natalia Santos, Fraga Silvestre De Souza, Andrea Vieira, Ariane
Source	Elsevier; Medline; PMC; WHO
abstract	BACKGROUND: Angiotensin-converting enzyme-2 (ACE2) may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). Because renin-angiotensin system blockers increase levels of ACE2, a protein that facilitates coronavirus entry into cells, there is concern that these drugs could increase the risk of developing a severe and fatal form of COVID-19. The impact of discontinuing ACEI and ARBs in patients with COVID-19 remains uncertain. DESIGN BRACE CORONA is a pragmatic, multicenter, randomized, phase IV, clinical trial that aims to enroll around 500 participants at 32 sites in Brazil. Participants will be identified from an ongoing national registry of suspected and confirmed cases of COVID-19. Eligible patients using renin-angiotensin system blockers (ACEI/ARBs) with a confirmed diagnosis of COVID-19 will be randomized to a strategy of continued ACEI/ARB treatment versus temporary discontinuation for 30 days. The primary outcome is the median days alive and out of the hospital at 30 days. Secondary outcomes include progression of COVID-19 disease, all-cause mortality, death from vascular causes, myocardial infarction, stroke, transient ischemic attack, new or worsening heart failure, myocarditis, pericarditis, arrhythmias, thromboembolic events, hypertensive crisis, respiratory failure, hemodynamic decompensation, sepsis, renal failure, troponin, B-type natriuretic peptide, N-terminal-pro hormone and D-dimer levels. SUMMARY: BRACE CORONA will evaluate whether the strategy of continued ACEI/ARB therapy compared with temporary discontinuation of these drugs impacts clinical outcomes among patients with COVID-19.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1016/j.ahj.2020.05.002
bibo:pmid	32405071
has license	no-cc
sha1sum (hex)	6e50ca2dec6d2808a5bd0f0a06b0a985e25a74f9
schema:url	https://doi.org/10.1016/j.ahj.2020.05.002
resource representing a document's title	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has PubMed Central identifier	PMC7219415
has PubMed identifier	32405071
schema:publication	Am Heart J
resource representing a document's body	covid:6e50ca2dec6d2808a5bd0f0a06b0a985e25a74f9#body_text
is schema:about of	named entity 'Journal' named entity 'Impact' named entity 'blockers' named entity 'angiotensin receptor blockers' named entity 'ACEI' named entity 'myocarditis' named entity 'inflammation' named entity 'nitrates' named entity 'clinical characteristics' named entity 'blood pressure' named entity 'short half-life' named entity 'receptor' named entity 'vasodilators' named entity 'Kruskal-Wallis test' named entity 'phase IV' named entity 'Ang II' named entity 'parenteral' named entity 'comorbidities' named entity 'binomial models' named entity 'ARBs' named entity 'phase III trials' named entity 'prognosis' named entity 'ACEI' named entity 'pro-inflammatory' named entity 'BNP' named entity 'COVID' named entity 'cardiovascular events' named entity 'Hypertension' named entity 'anti-inflammatory' named entity 'sample size' named entity 'renin-angiotensin' named entity 'calcium channel antagonists' named entity 'agonism' named entity 'heart failure' named entity 'randomized clinical trial' named entity 'Renin-angiotensin' named entity 'Ang II' named entity 'acute lung injury' named entity 'hydralazine' named entity 'ACEI' named entity 'COVID' named entity 'supportive care' named entity 'Brazilian Ministry of Health' named entity 'ACE2' named entity 'renin-angiotensin' named entity 'ventricular remodeling' named entity 'thromboembolic' named entity 'ACEI' named entity 'P-values' named entity 'medical therapy' named entity 'diuretics' named entity 'heart failure' named entity 'B-type natriuretic peptide' named entity 'observational studies' named entity 'COVID' named entity 'fibrosis' named entity 'PAI-1' named entity 'angiotensin II' named entity 'anti-hypertensive' named entity 'inflammation' named entity 'COVID' named entity 'stroke' named entity 'angiotensin' named entity 'ARBs' named entity 'heart failure'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software